A detailed history of Voloridge Investment Management, LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Voloridge Investment Management, LLC holds 235,962 shares of RGNX stock, worth $2.54 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
235,962
Previous 37,720 525.56%
Holding current value
$2.54 Million
Previous $677,000 634.27%
% of portfolio
0.02%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$12.17 - $24.61 $2.41 Million - $4.88 Million
198,242 Added 525.56%
235,962 $4.97 Million
Q4 2023

Feb 14, 2024

BUY
$12.89 - $20.82 $486,210 - $785,330
37,720 New
37,720 $677,000
Q1 2022

May 16, 2022

SELL
$24.62 - $34.31 $329,218 - $458,793
-13,372 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$30.19 - $40.28 $2.27 Million - $3.02 Million
-75,032 Reduced 84.87%
13,372 $437,000
Q3 2021

Nov 15, 2021

BUY
$29.09 - $45.68 $2.57 Million - $4.04 Million
88,404 New
88,404 $3.71 Million
Q1 2021

May 17, 2021

SELL
$33.61 - $49.95 $410,848 - $610,588
-12,224 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$26.52 - $49.35 $324,180 - $603,254
12,224 New
12,224 $554,000
Q3 2020

Nov 16, 2020

SELL
$27.01 - $40.26 $1.21 Million - $1.8 Million
-44,692 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$27.75 - $43.44 $1.04 Million - $1.63 Million
37,433 Added 515.68%
44,692 $1.65 Million
Q1 2020

May 15, 2020

BUY
$21.5 - $54.2 $156,068 - $393,437
7,259 New
7,259 $235,000
Q1 2019

May 15, 2019

SELL
$40.82 - $62.45 $363,012 - $555,367
-8,893 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$39.11 - $75.15 $1.27 Million - $2.44 Million
-32,449 Reduced 78.49%
8,893 $373,000
Q3 2018

Nov 14, 2018

BUY
$65.0 - $82.15 $2.69 Million - $3.4 Million
41,342 New
41,342 $3.12 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $465M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.